Lazard Asset Management
VTYX

Lazard Asset Management’s Ventyx Biosciences VTYX Stock Holding History

Lazard Asset Management’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,522
Closed -$285K – 2553
2023
Q1 		$285K Buy
+8,522
New +$331K ﹤0.01% 1226

Other funds holding VTYX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Lazard Asset Management's VTYX Position: Q2 2023 in Review

Lazard Asset Management sold out of Ventyx Biosciences (VTYX) in Q2 2023, closing a stake of 8,522 shares — an estimated $285K sold.

Lazard Asset Management first reported a position in VTYX in Q1 2023 and held it in 1 quarter. The position peaked at $285K in Q1 2023. 150 funds tracked by Wall St. Rank hold VTYX as of Q2 2023.

  • Lazard Asset Management reported no remaining Ventyx Biosciences position as of Q2 2023 after selling out during the quarter.
  • Lazard Asset Management sold 8,522 Ventyx Biosciences shares in Q2 2023, an estimated $285K.
  • Lazard Asset Management first reported a position in Ventyx Biosciences in Q1 2023 and held it in 1 quarter.
  • Lazard Asset Management's Ventyx Biosciences position peaked at $285K in Q1 2023.
  • 150 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2023.

Based on Lazard Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.